A Unique Story in Neonatal Research: The Development of a Porcine Surfactant

  title={A Unique Story in Neonatal Research: The Development of a Porcine Surfactant},
  author={Tore Curstedt and Henry L. Halliday and Christian Paul Speer},
  pages={321 - 329}
Surfactant deficiency was identified as the cause of respiratory distress syndrome (RDS) as long ago as 1959. Trials of surfactant replacement in the 1960s were unsuccessful because the preparations used contained only phospholipids and they were administered inefficiently by nebulization. In the 1970s Bengt Robertson and Göran Enhörning showed that natural surfactant, containing both phospholipids and proteins, could ameliorate the signs of RDS in immature rabbits. In the 1980s Bengt Robertson… 

Figures from this paper

30 Years of Surfactant Research - From Basic Science to New Clinical Treatments for the Preterm Infant

There is mounting evidence that early continuous positive airway pressure from birth is feasible and safe even in very preterm infants and that a strategy for surfactant administration should be part of a noninvasive ventilation approach.

A recipe for a good clinical pulmonary surfactant

Treatment of Respiratory Distress Syndrome with Single Recombinant Polypeptides that Combine Features of SP-B and SP-C.

Single polypeptides that combine properties of SP-B and SP-C are designed and produced recombinantly using a novel solubility tag based on spider silk production and are as efficient as nature-derived surfactant preparations against neonatal RDS in premature rabbit fetuses.

Development of novel synthetic lung surfactants for treatment of respiratory distress syndrome

This thesis designs and investigates the novel concept of creating surfactant protein analogues that combine both SP-B and SP-C activities in one polypeptide and designs and tests mixtures containing low amounts of Combo peptides that improve lung function and attenuates inflammation in a model of acute respiratory distress syndrome in adult rabbits.

The fascinating story of surfactant

  • H. Halliday
  • Medicine
    Journal of paediatrics and child health
  • 2017
It is remarkable that three men working on chemical warfare projects in three countries in the 1950s came to similar conclusions independently (see Fig. 1) about the importance of surfactant.

Synthetic surfactants with SP‐B and SP‐C analogues to enable worldwide treatment of neonatal respiratory distress syndrome and other lung diseases

There is a need to develop well‐defined synthetic replicas based on key components of natural surfactant to enable cost‐efficient production and facilitate the development of the treatments of other lung diseases than neonatal RDS.

Phospholipid Composition in Synthetic Surfactants Is Important for Tidal Volumes and Alveolar Stability in Surfactant-Treated Preterm Newborn Rabbits

Synthetic surfactant consisting of unsaturated and saturated phosphatidylcholines, POPG and the analogues of SP-B and SP-C has similar activity as Curosurf regarding VT and LGV in an animal model using preterm newborn rabbits ventilated without positive end-expiratory pressure.

Sharing Progress in Neonatal (SPIN) Lung and Brain

The first Sharing Progress in Neonatology (SPIN) meeting incorporating the 31st International Workshop on Surfactant Replacement took place in Naples from June 3–4, 2016, and it was fitting that this meeting should be held in Italy where the surfactant poractant alfa is manufactured for the treatment of preterm infants with respiratory distress syndrome.

A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome

Both CHF5633 doses were well tolerated and showed promising clinical efficacy profile, and encouraging data provide a basis for ongoing randomised controlled trials.

Impact of the New Generation Reconstituted Surfactant CHF5633 on Human CD4+ Lymphocytes

In vitro data indicate that CHF5633 does not exert unintended pro-inflammatory effects on non-activated and activated CD4+ T cells and that it might lack an overall reductive ability in comparison to animal-derived surfactants, potentially leaving pro- and anti-inflammatory cytokine response in balance.



History of Surfactant from 1980

Comparison studies show that multiple doses may be needed if surfactant is used to treat established RDS but early or prophylactic treatment is superior for infants with gestational ages less than 30 weeks, and a meta-analysis of 5 comparative studies suggests that a dose of 200 mg/kg of poractant alfa is associated with lower mortality compared with 100 mg/ kg of beractant.

Severe Neonatal Respiratory Distress Syndrome Treated with the Isolated Phospholipid Fraction of Natural Surfactant

Since the results show a significant improvement in lung function after replacement therapy, the efficacy of this new surfactant preparation should be further tested in randomized clinical trials.

Randomized clinical trial comparing two natural surfactant preparations to treat respiratory distress syndrome

  • M. HammoudN. Al-Kazmi H. Elsori
  • Medicine
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • 2004
Improved oxygenation and reduced ventilatory requirements were greater with Survanta compared to Alveofact, which in turn was associated with a trend towards a lower incidence of serious pulmonary complications.

Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome.

Comparative trials demonstrate greater early improvement in the requirement for ventilator support, fewer pneumothoraces, and fewer deaths associated with natural surfactant extract treatment, as well as a marginal decrease in the risk of bronchopulmonary dysplasia or mortality associated with the use of natural surfACTant preparations.

New Surfactant with SP-B and C Analogs Gives Survival Benefit after Inactivation in Preterm Lambs

It is hypothesized that CHF 5633 is also resistant to inactivation by serum albumin in vivo, and for the first time a synthetic surfactant containing both surfACTant protein B and C analogs showed significant benefit over animal derived surfactants in an in vivo model of surfactan inactivation in premature lambs.

Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants.

The effect of administration of different animal-derived surfactant extracts on the risk of mortality, chronic lung disease, and other morbidities associated with prematurity in preterm infants at risk for or having respiratory distress syndrome (RDS) is compared.

Surfactant Replacement Therapy for Severe Neonatal Respiratory Distress Syndrome: An International Randomized Clinical Trial

  • Medicine
  • 1988
Treatment with this surfactant appears to effectively improve lung function and short-term outcome in infants with severe neonatal respiratory distress syndrome.

Randomized multicentre trial of treatment with porcine natural surfactant for moderately severe neonatal respiratory distress syndrome

The data suggest that treatment with surfactant when RDS is moderately severe prevents or reverses the natural progression of the disease in at least 50% of the cases and lowers the risk of serious complications.

Efficacy of Porcine Versus Bovine Surfactants for Preterm Newborns With Respiratory Distress Syndrome: Systematic Review and Meta-analysis

There were significant reductions in deaths and the need for redosing with high-dose poractant alfa but not low- dose poractan alfa, compared with beractant, among preterm infants with respiratory distress syndrome.